HMH Maestro

Hospitals & Locations

James K. McCloskey II, M.D., Named Division Chief of the Division of Leukemia at JTCC

Hackensack University Medical CenterJohn Theurer Cancer CenterOncology

What you need to know

James K. McCloskey II, M.D., was named division chief of the division of Leukemia at John Theurer Cancer Center. Dr. McCloskey previously served as the interim chief for the Division of Leukemia and will continue in his role as director for the Program for Myeloproliferative Neoplasms at John Theurer Cancer Center.

James K. McCloskey II, M.D.

Dr. McCloskey specializes in the care of patients with acute leukemia, myelodysplastic syndrome (MDS), and myeloproliferative diseases. Before his appointment at JTCC, he was the chief fellow in the Department of Hematology and Oncology at Georgetown University Hospital, where he also completed his residency. He earned his medical degree from Georgetown University School of Medicine. His research interests focus on developmental therapeutics for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative disorders, including chronic myelogenous leukemia (CML).


Dr. McCloskey has extensive research experience, serving as primary investigator on multiple clinical trials, including those evaluating IDH inhibitors in AML, novel therapies for MDS, and pacritinib for patients with myelofibrosis. He has authored or coauthored numerous publications, including book chapters, reviews, and abstracts. He has published research on the treatment of adolescent ALL patients with pediatric-inspired induction regimens, as well as the outcomes of AML patients with monocytic differentiation.


Dr. McCloskey has presented a range of clinical work at major medical conferences, including meetings of the American Society of Hematology, American Society of Clinical Oncology, Georgetown University Research Day, and the Society of Comparative and Integrative Biology. His research was published in Blood, Advances in Clinical Oncology, OncoTargets and Therapy, and Breast Cancer Research and Treatment.